STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Biomedical Innovations and Engineering Original Research

Development of Formulation for Dry Powder Inhalation of Amino Acids Aimed at Smoking Cessation: A Biomedical Perspective

  1. H. Padma Latha Department of Pharmaceutics, Gyana Jyothy College of Pharmacy, Hyderabad
  2. Syed Riaz Hussain Chistia Department of Pharmaceutics, Gyana Jyothy College of Pharmacy
  3. N. Jyothi Reddy Department of Pharmaceutics, Gyana Jyothy College of Pharmacy

Abstract

This study aims to develop an effective and compliant therapy targeting the lungs through the strategic utilization of amino acids, which play a crucial role in modulating mood and behavior during activities like smoking. L-Tryptophan and L-Tyrosine were finely micronized within the 2–4 µm range, with lactose serving as a carrier, to create a dry powder inhalation formulation. The combination of these amino acids is anticipated to elicit a synergistic effect aimed at mitigating withdrawal symptoms associated with smoking cessation treatment. In vivo study findings revealed a rapid onset of action, heightened local drug concentration, and prolonged retention of the drug at the administration site. Consequently, this study’s conclusion emphasizes that the dry powder inhalation formulation represents an efficacious means of delivering drugs to the lungs compared to alternative administration routes, thereby promoting patient compliance and adherence to therapy. Through this approach, the therapy seeks to provide an optimized means of addressing the challenges associated with smoking cessation and enhancing patient outcomes therapy. The synergy between these amino acids aims to alleviate withdrawal symptoms in smoking cessation. In vivo studies demonstrated swift action, concentrated drug delivery, and prolonged drug presence at the site of administration. Consequently, this study concludes that the dry powder inhalation method offers an effective means of lung drug delivery compared to other routes, enhancing patient compliance and treatment adherence. This innovative therapy approach endeavors to address the complexities of smoking cessation and improve patient outcomes.

Keywords

References (27)

  1. Paranjpe M, Müller-Goymann C. Nanoparticle-Mediated Pulmonary Drug Delivery: A Review. International Journal of Molecular Sciences. 2014;15(4):5852-5873. doi:10.3390/ijms15045852
  2. Okamoto H, Danjo K. Application of supercritical fluid to preparation of powders of high-molecular weight drugs for inhalation. Advanced Drug Delivery Reviews. 2008;60(3):433-446. doi:10.1016/j.addr.2007.02.002
  3. Mahmud A, Discher DE. Lung vascular targeting through inhalation delivery: Insight from filamentous viruses and other shapes. IUBMB Life. 2011;63(8):607-612. doi:10.1002/iub.481
  4. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends in Biotechnology. 2007;25(12):563-570. doi:10.1016/j.tibtech.2007.09.005
  5. Bhavane R, Karathanasis E, Annapragada AV. Agglomerated vesicle technology: a new class of particles for controlled and modulated pulmonary drug delivery. Journal of Controlled Release. 2003;93(1):15-28. doi:10.1016/s0168-3659(03)00359-6
  6. Thorley AJ, Tetley TD. New perspectives in nanomedicine. Pharmacology & Therapeutics. 2013;140(2):176-185. doi:10.1016/j.pharmthera.2013.06.008
  7. Preedy E.C., Prokopovich P. Inhaler Devices. Elsevier; New York, NY, USA: 2013. Novel coatings and biotechnology trends in inhaler devices; pp. 37–50. [Google Scholar]
  8. ALPAR H, SOMAVARAPU S, ATUAH K, BRAMWELL V. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Advanced Drug Delivery Reviews. 2005;57(3):411-430. doi:10.1016/j.addr.2004.09.004
  9. Hamedinasab H, Rezayan AH, Mellat M, Mashreghi M, Jaafari MR. Development of chitosan-coated liposome for pulmonary delivery of N-acetylcysteine. International Journal of Biological Macromolecules. 2020;156:1455-1463. doi:10.1016/j.ijbiomac.2019.11.190
  10. Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim KJ, et al. The Particle has Landed—Characterizing the Fate of Inhaled Pharmaceuticals. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2010;23(S2):S-71-S-87. doi:10.1089/jamp.2010.0836
  11. Kanig JL. Pharmaceutical Aerosols. Journal of Pharmaceutical Sciences. 1963;52(6):513-535. doi:10.1002/jps.2600520603
  12. Bosquillon C, Lombry C, Preat V, Vanbever R. Comparison of particle sizing techniques in the case of inhalation dry powders. Journal of Pharmaceutical Sciences. 2001;90(12):2032-2041. doi:10.1002/jps.1154
  13. El-Sherbiny I.M., Villanueva D.G., Herrera D., Smyth H.D.C. Controlled Pulmonary Drug Delivery. Springer; New York, NY, USA: 2011. Overcoming Lung Clearance Mechanisms for Controlled Release Drug Delivery; pp. 101–126. [Google Scholar]
  14. Chew NYK, Chan HK. The Role of Particle Properties in Pharmaceutical Powder Inhalation Formulations. Journal of Aerosol Medicine. 2002;15(3):325-330. doi:10.1089/089426802760292672
  15. Chen L, Okuda T, Lu XY, Chan HK. Amorphous powders for inhalation drug delivery. Advanced Drug Delivery Reviews. 2016;100:102-115. doi:10.1016/j.addr.2016.01.002
  16. D. Ticehurst M, A. Basford P, I. Dallman C, M. Lukas T, V. Marshall P, Nichols G, et al. Characterisation of the influence of micronisation on the crystallinity and physical stability of revatropate hydrobromide. International Journal of Pharmaceutics. 2000;193(2):247-259. doi:10.1016/s0378-5173(99)00347-6
  17. Mackin L., Zanon R., Park J.M., Foster K., Opalenik H., Demonte M. Quantification of low levels (<10%) of amorphous content in micronised active batches using dynamic vapour sorption and isothermal microcalorimetry. Int. J. Pharm. 2002;231:227–236. [PubMed] [Google Scholar]
  18. Jain M.S., Lohare G.B., Bari M.M., Chavan R.B., Barhate S.D., Shah C.B. Spray Drying in Pharmaceutical Industry: A Review. Res. J. Pharm. Dos. Forms Technol. 2012;4:74–79. [Google Scholar]
  19. Leung SSY, Parumasivam T, Gao FG, Carrigy NB, Vehring R, Finlay WH, et al. Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections. Pharmaceutical Research. 2016;33(6):1486-1496. doi:10.1007/s11095-016-1892-6
  20. Panão M.O., Moreira A.L.N., Vicente J., Costa E. Assessment of ultrasonic sprays for spray drying. Assessment. 2014;7:10. [Google Scholar]
  21. Joshi J.T. A review on micronization techniques. J. Pharm. Sci. Technol. 2011;3:651–681. [Google Scholar]
  22. Otake H, Okuda T, Okamoto H. Development of Spray-Freeze-Dried Powders for Inhalation with High Inhalation Performance and Antihygroscopic Property. CHEMICAL & PHARMACEUTICAL BULLETIN. 2016;64(3):239-245. doi:10.1248/cpb.c15-00824
  23. Kondo M, Niwa T, Okamoto H, Danjo K. Particle Characterization of Poorly Water-Soluble Drugs Using a Spray Freeze Drying Technique. Chemical and Pharmaceutical Bulletin. 2009;57(7):657-662. doi:10.1248/cpb.57.657
  24. Ishwarya SP, Anandharamakrishnan C, Stapley AGF. Spray-freeze-drying: A novel process for the drying of foods and bioproducts. Trends in Food Science & Technology. 2015;41(2):161-181. doi:10.1016/j.tifs.2014.10.008
  25. Ali ME, Lamprecht A. Spray freeze drying for dry powder inhalation of nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics. 2014;87(3):510-517. doi:10.1016/j.ejpb.2014.03.009
  26. Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Advanced Drug Delivery Reviews. 2006;58(9-10):1009-1029. doi:10.1016/j.addr.2006.07.010
  27. Davies OR, Lewis AL, Whitaker MJ, Tai H, Shakesheff KM, Howdle SM. Applications of supercritical CO2 in the fabrication of polymer systems for drug delivery and tissue engineering. Advanced Drug Delivery Reviews. 2008;60(3):373-387. doi:10.1016/j.addr.2006.12.001